Trial Search Results
A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty
This study will evaluate the safety, tolerability and effect of GRF6021 on clinical recovery parameters in patients undergoing primary hip or knee arthroplasty.
Stanford is currently not accepting patients for this trial.
- Biological: GRF6021
- Other: Placebo
- Men and women 50-85 years of age scheduled to undergo primary total hip or knee
- Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 .
- Blood coagulation disorders.
- Subjects who started chronic anticoagulant therapy (warfarin, heparin, low-molecular
weight heparin, or Factor Xa inhibitors) in the last 6 months
- Hypercoagulable state.
- Prior hypersensitivity to any human blood product including plasma.
- Treatment with any human blood product, including transfusions and IV immunoglobulin,
during the 6 months prior to screening.
- History of immunoglobulin A or haptoglobin deficiency.
- Major surgery, trauma or injury in the last 3 months or minor surgery in the last 1
- Heart disease or congestive heart failure in the 6 months prior to dosing.
- Poorly controlled hypertension.
- Severe anemia.
- Functional impairment of major joint or lower extremity other than joint undergoing
Ages Eligible for Study
50 Years - 85 Years
Genders Eligible for Study